Previous close | 0.8900 |
Open | 0.8805 |
Bid | 0.7226 x 100 |
Ask | 0.8059 x 100 |
Day's range | 0.7000 - 0.9140 |
52-week range | 0.7000 - 21.8000 |
Volume | |
Avg. volume | 176,536 |
Market cap | 4.601M |
Beta (5Y monthly) | -0.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -26.0000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.00 |
CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders’ Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended March 31, 2024, and provided a clinical
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that longstanding Cingulate investor and board member Peter J. Werth will join Cingulate Chairman and CEO Shane J. Schaffer in a live Benzinga All Access event on Friday May 3, 2024, at 12:10 p.m. EST. M
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 conference on Wednesday, May 1, 2024, at 2:30 PM PST. Management will also host individual investor meetings on Thursday, May 2. Meetings